Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $12,001,300,000 | reported | |
| FY 2024 | 2024-12-31 | $11,020,100,000 | reported | |
| FY 2023 | 2023-12-31 | $9,869,200,000 | reported | |
| FY 2022 | 2022-12-31 | $8,930,700,000 | reported | |
| FY 2021 | 2021-12-31 | $7,574,400,000 | reported | |
| FY 2020 | 2020-12-31 | $6,205,700,000 | reported | |
| FY 2019 | 2019-12-31 | $4,162,800,000 | reported | |
| FY 2018 | 2018-12-31 | $3,047,597,000 | reported | |
| FY 2017 | 2017-12-31 | $2,488,652,000 | reported | |
| FY 2016 | 2016-12-31 | $1,702,177,000 | reported | |
| FY 2015 | 2015-12-31 | $1,032,336,000 | reported | |
| FY 2014 | 2014-12-31 | $580,415,000 | reported |
Vertex Pharmaceuticals Inc · CIK 875320 · Engraved from SEC EDGAR
Twelve months to Sep 30, 2026 · derived
Vertex Pharmaceuticals Inc is the 13th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
Latest filing Nov 18, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $2.02B | $2.02B | — | 254.03M sh | −1.1% | 63.2% |
| FY2024 | — | $1.18B | $1.18B | — | 256.79M sh | −0.6% | — |
| FY2023 | — | $427.60M | $427.60M | — | 258.31M sh | +0.5% | 12.8% |
| FY2022 | — | $0.00 | $0.00 | — | 257.09M sh | +1.0% | 0.0% |
| FY2021 | — | $1.43B | $1.43B | — | 254.58M sh | −2.1% | 59.2% |
1,797 managers · Quarter ended Sep 30, 2026All holders ›
151